Johnson & Johnson Price to Sales Ratio 2012-2026 | JNJ
Historical PS ratio values for Johnson & Johnson (JNJ) over the last 10 years. The current P/S ratio for Johnson & Johnson as of June 16, 2026 is .
| Johnson & Johnson P/S Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Sales per Share | Price to Sales Ratio |
| 2026-06-17 | 234.20 | 5.91 | |
| 2026-03-31 | 243.02 | $39.65 | 6.13 |
| 2025-12-31 | 204.66 | $38.84 | 5.27 |
| 2025-09-30 | 182.21 | $38.00 | 4.80 |
| 2025-06-30 | 149.01 | $37.37 | 3.99 |
| 2025-03-31 | 160.41 | $36.83 | 4.36 |
| 2024-12-31 | 138.77 | $36.59 | 3.79 |
| 2024-09-30 | 154.27 | $35.68 | 4.32 |
| 2024-06-30 | 138.09 | $34.80 | 3.97 |
| 2024-03-31 | 148.25 | $33.72 | 4.40 |
| 2023-12-31 | 145.79 | $32.94 | 4.43 |
| 2023-09-30 | 143.72 | $29.30 | 4.91 |
| 2023-06-30 | 151.63 | $28.44 | 5.33 |
| 2023-03-31 | 140.93 | $29.25 | 4.82 |
| 2022-12-31 | 159.47 | $30.01 | 5.31 |
| 2022-09-30 | 146.52 | $28.96 | 5.06 |
| 2022-06-30 | 158.15 | $30.17 | 5.24 |
| 2022-03-31 | 156.90 | $29.89 | 5.25 |
| 2021-12-31 | 150.48 | $29.46 | 5.11 |
| 2021-09-30 | 141.13 | $34.22 | 4.12 |
| 2021-06-30 | 143.11 | $33.39 | 4.29 |
| 2021-03-31 | 141.89 | $31.54 | 4.50 |
| 2020-12-31 | 135.03 | $30.94 | 4.36 |
| 2020-09-30 | 126.86 | $30.25 | 4.19 |
| 2020-06-30 | 119.04 | $30.12 | 3.95 |
| 2020-03-31 | 110.23 | $30.88 | 3.57 |
| 2019-12-31 | 121.84 | $30.55 | 3.99 |
| 2019-09-30 | 107.33 | $30.30 | 3.54 |
| 2019-06-30 | 114.68 | $29.99 | 3.82 |
| 2019-03-31 | 114.32 | $30.01 | 3.81 |
| 2018-12-31 | 104.84 | $29.91 | 3.50 |
| 2018-09-30 | 111.54 | $29.79 | 3.74 |
| 2018-06-30 | 97.30 | $29.51 | 3.30 |
| 2018-03-31 | 102.01 | $28.73 | 3.55 |
| 2017-12-31 | 110.51 | $27.86 | 3.97 |
| 2017-09-30 | 102.20 | $26.99 | 3.79 |
| 2017-06-30 | 103.34 | $26.21 | 3.94 |
| 2017-03-31 | 96.65 | $25.95 | 3.72 |
| 2016-12-31 | 88.82 | $25.74 | 3.45 |
| 2016-09-30 | 90.44 | $25.58 | 3.54 |
| 2016-06-30 | 92.25 | $25.27 | 3.65 |
| 2016-03-31 | 81.71 | $24.98 | 3.27 |
| 2015-12-31 | 77.01 | $24.90 | 3.09 |
| 2015-09-30 | 69.47 | $24.94 | 2.79 |
| 2015-06-30 | 71.98 | $25.29 | 2.85 |
| 2015-03-31 | 73.76 | $25.75 | 2.86 |
| 2014-12-31 | 76.14 | $25.91 | 2.94 |
| 2014-09-30 | 77.11 | $25.91 | 2.98 |
| 2014-06-30 | 75.18 | $25.56 | 2.94 |
| 2014-03-31 | 70.10 | $24.96 | 2.81 |
| 2013-12-31 | 64.89 | $24.78 | 2.62 |
| 2013-09-30 | 60.99 | $24.65 | 2.47 |
| 2013-06-30 | 59.96 | $24.60 | 2.44 |
| 2013-03-31 | 56.51 | $24.30 | 2.33 |
| 2012-12-31 | 48.20 | $24.00 | 2.01 |
| 2012-09-30 | 46.97 | $23.61 | 1.99 |
| 2012-06-30 | 45.63 | $23.32 | 1.96 |
| 2012-03-31 | 44.12 | $23.40 | 1.89 |
| 2011-12-31 | 43.48 | $23.42 | 1.86 |
| 2011-09-30 | 41.84 | $23.17 | 1.81 |
| 2011-06-30 | 43.32 | $22.79 | 1.90 |
| 2011-03-31 | 38.25 | $22.30 | 1.72 |
| 2010-12-31 | 39.57 | $22.06 | 1.79 |
| 2010-09-30 | 39.30 | $22.38 | 1.76 |
| 2010-06-30 | 37.11 | $22.40 | 1.66 |
| 2010-03-31 | 40.60 | $22.40 | 1.81 |
| 2009-12-31 | 39.80 | $22.20 | 1.79 |
| 2009-09-30 | 37.33 | $21.62 | 1.73 |
| 2009-06-30 | 34.55 | $21.84 | 1.58 |
| 2009-03-31 | 31.71 | $22.15 | 1.43 |
| 2008-12-31 | 35.77 | $22.41 | 1.60 |
| 2008-09-30 | 41.08 | $22.54 | 1.82 |
| 2008-06-30 | 37.91 | $22.05 | 1.72 |
| 2008-03-31 | 37.95 | $21.45 | 1.77 |
| 2007-12-31 | 38.76 | $20.94 | 1.85 |
| 2007-09-30 | 37.95 | $20.08 | 1.89 |
| 2007-06-30 | 35.35 | $19.45 | 1.82 |
| 2007-03-31 | 34.35 | $18.76 | 1.83 |
| 2006-12-31 | 37.41 | $17.96 | 2.08 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $574.358B | $94.193B |
| Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |